POLG

Chr 15ARAD

DNA polymerase gamma, catalytic subunit

Also known as: MDP1, MIRAS, MTDPS4A, MTDPS4B, PEO, POLG1, POLGA, PolG-alpha

Mitochondrial DNA polymerase is heterotrimeric, consisting of a homodimer of accessory subunits plus a catalytic subunit. The protein encoded by this gene is the catalytic subunit of mitochondrial DNA polymerase. The encoded protein contains a polyglutamine tract near its N-terminus that may be polymorphic. Defects in this gene are a cause of progressive external ophthalmoplegia with mitochondrial DNA deletions 1 (PEOA1), sensory ataxic neuropathy dysarthria and ophthalmoparesis (SANDO), Alpers-Huttenlocher syndrome (AHS), and mitochondrial neurogastrointestinal encephalopathy syndrome (MNGIE). Two transcript variants encoding the same protein have been found for this gene. [provided by RefSeq, Jul 2008]

Primary Disease Associations & Inheritance

Mitochondrial DNA depletion syndrome 4A (Alpers type)MIM #203700
AR
Mitochondrial DNA depletion syndrome 4B (MNGIE type)MIM #613662
AR
Mitochondrial recessive ataxia syndrome (includes SANDO and SCAE)MIM #607459
AR
Progressive external ophthalmoplegia, autosomal dominant 1MIM #157640
AD
Progressive external ophthalmoplegia, autosomal recessive 1MIM #258450
AR
UniProtSensory ataxic neuropathy dysarthria and ophthalmoparesis
UniProtLeigh syndrome
UniProtSpinocerebellar ataxia with epilepsy
586
ClinVar variants
83
Pathogenic / LP
0.00
pLI score
2
Active trials
Clinical Summary— POLG
🧬
Gene-Disease Validity (ClinGen)
Leigh syndrome · ARLimited

Limited evidence — not for standalone diagnostic reporting

âš¡
Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
83 Pathogenic / Likely Pathogenic· 288 VUS of 586 total submissions
💊
Clinical Trials
2 active or recruiting trials — potential therapeutic options may be available

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Moderate LoF intolerance
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
0.56LOEUF
pLI 0.000
Z-score 4.54
OE 0.40 (0.29–0.56)
Moderately constrained

More LoF-intolerant than ~75% of genes

Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
-0.74Z-score
OE missense 1.08 (1.01–1.14)
770 obs / 714.2 exp
Tolerant

Tolerant to missense variation

Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.40 (0.29–0.56)
0≤0.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.1.08 (1.01–1.14)
0≤0.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.1.13
0≤1.21.6
LoF obs/exp: 27 / 67.1Missense obs/exp: 770 / 714.2Syn Z: -1.77

ClinVar Variant Classifications

586 submitted variants in ClinVar

Classification Summary

Pathogenic33
Likely Pathogenic50
VUS288
Likely Benign207
Benign1
Conflicting7
33
Pathogenic
50
Likely Pathogenic
288
VUS
207
Likely Benign
1
Benign
7
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
12
4
17
0
33
Likely Pathogenic
23
17
10
0
50
VUS
2
252
32
2
288
Likely Benign
0
7
92
108
207
Benign
0
0
1
0
1
Conflicting
—7
Total37280152110586

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

POLG · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Gene2Phenotype Curations

POLG-related progressive external ophthalmoplegia

definitive
ADUndeterminedAltered Gene Product Structure
Eye
G2P ↗
missense variantinframe deletioninframe insertion

POLG-related mitochondrial ataxia syndrome

definitive
ARLoss Of FunctionAbsent Gene Product
Eye
G2P ↗

POLG-related mitochondrial DNA depletion syndrome, Alpers type

definitive
ARUndeterminedAltered Gene Product Structure
Dev. DisordersEye
G2P ↗
missense variantinframe deletioninframe insertion

Gene2Phenotype curations · DECIPHER consortium patient cohort (public variants) · deciphergenomics.org

OMIM — Genotype-Phenotype Relationships

1 OMIM entry

Mitochondrial DNA depletion syndrome 4A (Alpers type)

MIM #203700

Molecular basis of disorder known

Autosomal recessive

Mitochondrial DNA depletion syndrome 4B (MNGIE type)

MIM #613662

Molecular basis of disorder known

Autosomal recessive

Mitochondrial recessive ataxia syndrome (includes SANDO and SCAE)

MIM #607459

Molecular basis of disorder known

Autosomal recessive

Progressive external ophthalmoplegia, autosomal dominant 1

MIM #157640

Molecular basis of disorder known

Autosomal dominant

Progressive external ophthalmoplegia, autosomal recessive 1

MIM #258450

Molecular basis of disorder known

Autosomal recessive
📖
GeneReview available — POLG
Authoritative clinical overview · NCBI Bookshelf · Recommended first read
Open GeneReview ↗
Clinical Literature
Landmark / reviewRecent case evidence
Key Publications
Landmark & review papers · by relevance
PubMed
POLG-related disorders and their neurological manifestations.
Rahman S et al.·Nat Rev Neurol
2019Review
Mitochondrial Epilepsy, a Challenge for Neurologists.
Lopriore P et al.·Int J Mol Sci
2022Review
Mitochondrial DNA maintenance defects.
El-Hattab AW et al.·Biochim Biophys Acta Mol Basis Dis
2017Review
Review and Consensus on Pharmacogenomic Testing in Psychiatry.
Bousman CA et al.·Pharmacopsychiatry
2021Review
Mitochondrial Neurodegeneration.
Zeviani M et al.·Cells
2022Review
Primary mitochondrial diseases.
Pizzamiglio C et al.·Handb Clin Neurol
2024Review
Mitochondrial disease.
Schapira AH·Lancet
2006Review
Recent Gene-Specific Literature
Gene in title · MEDLINE · newest first
Europe PMC
Valproic Acid Therapy and POLG Genotype
Kane M.
2012🔓 Open Access
Model organisms in POLG-related disorders: insights from yeast to multicellular systems.
Casas RB et al.·Cell Death Dis
2025🔓 Open AccessFunctional
A Scoping Review of POLG-Related Cerebellar Ataxia: Insights and Clinical Perspectives.
Kalampokini S et al.·Tremor Other Hyperkinet Mov (N Y)
2025🔓 Open AccessReview